PDCD1 and non-small cell lung carcinoma: indicated that first-line pembrolizumab, one of immune checkpoint blockades (ICB) targeting PD-1, plus pemetrexed-carboplatin continued to show improved response and survival versus chemotherapy alone in advanced non-squamous non-small cell lung cancer (NSCLC) (33).